Drug intelligence / Profile preview

PTC-2113

Development stage: Preclinical
Lead developer: Eos Senolytix
Modality: Peptides
Administration: Subcutaneous

Overview

PTC-2113 is a preclinical-stage mitochondrial-targeted geropeptide being developed by Eos Senolytix for the treatment of obesity and glucose metabolic disorders. Powered by the proprietary MitoXcel™ technology platform, PTC-2113 is designed to target the age-associated decline in mitochondrial membrane potential (MMP, ΔΨm). Specifically, PTC-2113 acts via 'Mechanism 1' of the platform, which rapidly restores mitochondrial efficiency in aging cells, shifting them toward a youthful energetic phenotype and enhancing ATP production. This approach aims to improve metabolic health and body composition without directly targeting muscle or fat regulatory pathways.

Targets

Mitochondrial electron transport chain Complex III proteinsCOX7C (Cytochrome c oxidase subunit 7C, mitochondrial)bc1 complex (Cytochrome bc1 complex (plasmodium))

Beyond the preview

Go deeper on PTC-2113.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PTC-2113.